Cellceutix Announces Appointment of Vice President for Regulatory Affairs
September 16, 2016 11:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - September 16, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
September 13, 2016 08:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - September 13, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Corporation to Present at Upcoming Conferences
September 07, 2016 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - September 07, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
August 30, 2016 14:07 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - August 30, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
August 03, 2016 09:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - August 03, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
July 21, 2016 07:00 ET
|
Cellceutix
BEVERLY, MA --(Marketwired - July 21, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
July 18, 2016 10:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - July 18, 2016) - Cellceutix Corporation, (OTCQB: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis
July 07, 2016 08:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - July 07, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
June 30, 2016 13:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 30, 2016) - Cellceutix Corporation, (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis
June 15, 2016 11:45 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 15, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...